Griffin Maureen A, Culp William T N, Chohan Amandeep S, Johnson Eric G, Giuffrida Michelle A, Palm Carrie A, Rebhun Robert B, Kent Michael S
Department of Surgical and Radiological Sciences, From the University of California-Davis, School of Veterinary Medicine, Davis, Davis, California, United States of America.
Department of Medicine and Epidemiology, University of California-Davis, School of Veterinary Medicine, Davis, Davis, California, United States of America.
PLoS One. 2024 Dec 27;19(12):e0316080. doi: 10.1371/journal.pone.0316080. eCollection 2024.
The primary aim of this study was to evaluate the effects of vasodilator administration on CT angiography (CTA) prostatic artery diameter and peak opacification in dogs with prostatic carcinoma prior to prostatic artery embolization (PAE).
A prospective clinical trial was performed. Ten dogs with naturally occurring prostatic carcinoma and no evidence of cardiovascular disease were enrolled. Each dog underwent multiphase CTA of the prostate before and after IV vasodilator (glyceryl trinitrate [GTN] or clevidipine butyrate [clevidipine]) administration, and cardiovascular parameters were monitored. PAE was performed the following day. Prostatic arterial anatomy was characterized by CTA. Prostatic artery lumen diameter and peak opacification were measured on pre- and post-vasodilator CTA by a blinded radiologist. The percent change of these measurements was calculated and assessed for significance.
Glyceryl trinitrate and clevidipine were administered in 5 dogs each with subsequent blood pressure reduction documented in all dogs. No significant difference was detected in prostatic artery diameter or peak opacification between pre- vs. post-vasodilator CTA. Good agreement in prostatic arterial branch number, origin, and course was documented between pre- and post-vasodilator CTA images.
Study findings do not support the routine use of vasodilator administration during pre-PAE CTA in dogs, though larger sample sizes and protocol alterations may be needed to detect a clinically relevant utility.
本研究的主要目的是评估在前列腺动脉栓塞术（PAE）之前，给患有前列腺癌的犬类注射血管扩张剂对CT血管造影（CTA）前列腺动脉直径和峰值造影剂充盈的影响。
进行了一项前瞻性临床试验。纳入了10只患有自然发生的前列腺癌且无心血管疾病证据的犬。每只犬在静脉注射血管扩张剂（硝酸甘油[GTN]或丁酸氯维地平[clevidipine]）前后均接受前列腺多期CTA检查，并监测心血管参数。次日进行PAE。通过CTA对前列腺动脉解剖结构进行表征。由一位不知情的放射科医生在注射血管扩张剂前后的CTA上测量前列腺动脉管腔直径和峰值造影剂充盈。计算这些测量值的变化百分比并评估其显著性。
5只犬注射了硝酸甘油，5只犬注射了丁酸氯维地平，所有犬随后均出现血压下降。注射血管扩张剂前后的CTA在前列腺动脉直径或峰值造影剂充盈方面未检测到显著差异。注射血管扩张剂前后的CTA图像在前列腺动脉分支数量、起源和走行方面显示出良好的一致性。
研究结果不支持在犬类PAE前CTA检查期间常规使用血管扩张剂，尽管可能需要更大的样本量和方案调整来检测其临床相关效用。
